Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer

FASEB Journal

Volumn 21, Issue 10, 2007, Pages 2285-2293

  Birrell, Stephen N ^a   Butler, Lisa M ^a   Harris, Jonathan M ^b   Buchanan, Grant ^a,c   Tilley, Wayne D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Estrogen; Hormone replacement therapy; Medroxyprogesterone acetate; Signaling

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; CONTRACEPTIVE AGENT; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYDROXYFLUTAMIDE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RISK; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTINS; RECEPTORS, ANDROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 34547760403     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-7518com     Document Type: Review

References (107)

1. Cogliano, V., Grosse, Y., Baan, R., Straif, K., Secretan, B., and El Ghissassi, F. (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet. Oncol. 6, 552-553
2. Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 289, 3243-3253
3. Klaiber, E. L., Vogel, W., and Rako, S. (2005) A critique of the Women's Health Initiative hormone therapy study. Fertil. Steril. 84, 1589-1601
4. Clark, J. H. (2006) A critique of Women's Health Initiative Studies (2002-2006) (Online). Nucl. Recept. Signal. 4, e023
5. Kuhl, H. (2004) Is the elevated breast cancer risk observed in the WHI study an artifact? Climacteric. 7, 319-322
6. Lee, S. A., Ross, R. K., and Pike, M. C. (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer. 92, 2049-2058
7. Collins, J. A., Blake, J. M., and Crosignani, P. G. (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum. Reprod. Update. 11, 545-560
8. Shah, N. R., Borenstein, J., and Dubois, R. W. (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 12, 668-678
9. Speroff, L. (2004) Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. Maturitas 49, 51-57
10. Li, X., Lonard, D. M., and O'Malley, B. W. (2004) A contemporary understanding of progesterone receptor function. Mech. Ageing. Dev. 125, 669-678
11. Buchanan, G., Birrell, S. N., Peters, A. A., Bianco-Miotto, T., Ramsay, K., Cops, E. J., Yang, M., Harris, J. M., Simila, H. A., Moore, N. L., et al. (2005) Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 65, 8487-8496
12. Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., and Tilley, W. D. (1999) Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol. Cell Endocrinol. 154, 11-20
13. Ouatas, T., Halverson, D., and Steeg, P. S. (2003) Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin. Cancer Res. 9, 3763-3772
14. Pike, M. C., Spicer, D. V., Dahmoush, L., and Press, M. F. (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15, 17-35
15. Curtis Hewitt, S., Couse, J. F., and Korach, K. S. (2000) Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2, 345-352
16. Katzenellenbogen, B. S., and Frasor, J. (2004) Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 31, 28-38
17. Conneely, O. M., Jericevic, B. M., and Lydon, J. P. (2003) Progesterone receptors in mammary gland development and tumorigenesis. J. Mammary. Gland. Biol. Neoplasia. 8, 205-214
18. Graham, J. D., and Clarke, C. L. (1997) Physiological action of progesterone in target tissues. Endocr. Rev. 18, 502-519
19. Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., and Thijssen, J. H. (2003) Classification and pharmacology of progestins. Maturitas. 46. Suppl. 1, S7-S16
20. Sitruk-Ware, R. (2004) Pharmacological profile of progestins. Maturitas 47, 277-283
21. Campagnoli, C., Abba, C., Ambroggio, S., and Peris, C. (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J. Steroid. Biochem. Mol. Biol. 97, 441-450
22. Chabbert-Buffet, N., Meduri, G., Bouchard, P., and Spitz, I. M. (2005) Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 11, 293-307
23. Boonyaratanakornkit, V., and Edwards, D. P. (2004) Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays Biochem. 40, 105-120
24. Soderqvist, G., and von Schoultz, B. (2004) Lessons to be learned from clinical studies on hormones and the breast. Maturitas 49, 90-96
25. Santen, R. J. (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids. 68, 953-964
26. Pike, M. C., and Ross, R. K. (2000) Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 65, 659-664
27. Cline, J. M., Soderqvist, G., von Schoultz, E., Skoog, L., and von Schoultz, B. (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am. J. Obstet. Gynecol. 174, 93-100
28. Campagnoli, C., Clavel-Chapelon, F., Kaaks, R., Peris, C., and Berrino, F. (2005) Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J. Steroid. Biochem. Mol. Biol. 96, 95-108
29. Stahlberg, C., Pedersen, A. T., Lynge, E., and Ottesen, B. (2003) Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet. Gynecol. Scand. 82, 335-344
30. Magnusson, C., Baron, J. A., Correia, N., Bergstrom, R., Adami, H. O., and Persson, I. (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer. 81, 339-344
31. Stahlberg, C., Pedersen, A. T., Lynge, E., Andersen, Z. J., Keiding, N., Hundrup, Y. A., Obel, E. B., and Ottesen, B. (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int. J. Cancer. 109, 721-727
32. De Lignieres, B., de Vathaire, F., Fournier, S., Urbinelli, R., Allaert, F., Le, M. G., and Kuttenn, F. (2002) Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 5, 332-340
33. Fournier, A., Berrino, F., Riboli, E., Avenel, V., and Clavel-Chapelon, F. (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer. 114, 448-454
34. Zhou, J., Ng, S., Adesanya-Famuiya, O., Anderson, K., and Bondy, C. A. (2000) Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 14, 1725-1730
35. Wood, C. E., Register, T. C., Lees, C. J., Chen, H., Kimrey, S., and Mark Cline, J. (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast. Cancer Res. Treat. 101, 125-134
36. Birrell, S. N., Hall, R. E., and Tilley, W. D. (1998) Role of the androgen receptor in human breast cancer. J. Mammary. Gland. Biol. Neoplasia. 3, 95-103
37. Brys, M. (2000) Androgens and androgen receptor: do they play a role in breast cancer? Med. Sci. Monit. 6, 433-438
38. Liao, D. J., and Dickson, R. B. (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J. Steroid. Biochem. Mol. Biol. 20, 175-189
39. Langer, M., Kubista, E., Schemper, M., and Spona, J. (1990) Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch. Gynecol. Obstet. 247, 203-209
40. Labrie, F., Luu-The, V., Labrie, C., Belanger, A., Simard, J., Lin, S. X., and Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24, 152-182
41. Martel, C., Melner, M. H., Gagne, D., Simard, J., and Labrie, F. (1994) Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol. Cell. Endocrinol. 104, 103-111
42. Labrie, F. (2003) Extragonadal synthesis of sex steroids: intracrinology. Ann. Endocrinol. (Paris). 64, 95-107
43. Yeh, S., Hu, Y. C., Wang, P. H., Xie, C., Xu, Q., Tsai, M. Y., Dong, Z., Wang, R. S., Lee, T. H., and Chang, C. (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J. Exp. Med. 198, 1899-1908
44. Moinfar, F., Okcu, M., Tsybrovskyy, O., Regitnig, P., Lax, S. F., Weybora, W., Ratschek, M., Tavassoli, F. A., and Denk, H. (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98, 703-711
45. Ruizeveld de Winter, J. A., Trapman, J., Vermey, M., Mulder, E., Zegers, N. D., and van der Kwast, T. H. (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem. 39, 927-936
46. Janssen, P. J., Brinkmann, A. O., Boersma, W. J., and Van der Kwast, T. H. (1994) Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J. Histochem. Cytochem. 42, 1169-1175
47. Zhuang, Y. H., Saaristo, R., and Ylikomi, T. (2003) An in vitro long-term culture model for normal human mammary gland: expression and regulation of steroid receptors. Cell Tissue Res. 311, 217-226
48. Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., and Tilley, W. D. (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid. Biochem. Mol. Biol. 52, 459-467
49. Hackenberg, R., Luttchens, S., Hofmann, J., Kunzmann, R., Holzel, F., and Schulz, K. D. (1991) Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 51, 5722-5727
50. De Launoit, Y., Dauvois, S., Dufour, M., Simard, J., and Labrie, F. (1991) Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N, n-butyl-N-methyl-11-[16′ alpha-chloro-3′,17 beta-dihydroxy-estra-1′,3′,5′- (10′)triene-7′ alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res. 51, 2797-2802
51. Greeve, M. A., Allan, R. K., Harvey, J. M., and Bentel, J. M. (2004) Inhibition of MCF-7 breast cancer cell proliferation by 5alpha- dihydrotestosterone; a role for p21(Cip1/Waf1). J. Mol. Endocrinol. 32, 793-810
52. Dauvois, S., Geng, C. S., Levesque, C., Merand, Y., and Labrie, F. (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res. 51, 3131-3135
53. Ortmann, J., Prifti, S., Bohlmann, M. K., Rehberger-Schneider, S., Strowitzki, T., and Rabe, T. (2002) Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol. Endocrinol. 16, 113-120
54. Kandouz, M., Lombet, A., Perrot, J. Y., Jacob, D., Carvajal, S., Kazem, A., Rostene, W., Therwath, A., and Gompel, A. (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J. Steroid. Biochem. Mol. Biol. 69, 463-471
55. Lapointe, J., Fournier, A., Richard, V., and Labrie, C. (1999) Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 140, 416-421
56. Tormey, D. C., Lippman, M. E., Edwards, B. K., and Cassidy, J. G. (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. Intern. Med. 98, 139-144
57. Ingle, J. N., Twito, D. I., Schaid, D. J., Cullinan, S. A., Krook, J. E., Mailliard, J. A., Tschetter, L. K., Long, H. J., Gerstner, J. G., Windschitl, H. E., et al. (1991) Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 67, 886-891
58. Lea, O. A., Kvinnsland, S., and Thorsen, T. (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res. 49, 7162-7167
59. Hall, R. E., Aspinall, J. O., Horsfall, D. J., Birrell, S. N., Bentel, J. M., Sutherland, R. L., and Tilley, W. D. (1996) Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br. J. Cancer 74, 1175-1180
60. Kuenen-Boumeester, V., Van der Kwast, T. H., Claassen, C. C., Look, M. P., Liem, G. S., Klijn, J. G., and Henzen-Logmans, S. C. (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur. J. Cancer. 32A, 1560-1565
61. Honma, N., Sakamoto, G., Akiyama, F., Esaki, Y., Sawabe, M., Arai, T., Hosoi, T., Harada, N., Younes, M., and Takubo, K. (2003) Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 42, 120-127
62. Riva, C., Dainese, E., Caprara, G., Rocca, P. C., Massarelli, G., Tot, T., Capella, C., and Eusebi, V. (2005) Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows. Arch. 447, 695-700
63. Agoff, S. N., Swanson, P. E., Linden, H., Hawes, S. E., and Lawton, T. J. (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120, 725-731
64. Schippinger, W., Regitnig, P., Dandachi, N., Wernecke, K. D., Bauernhofer, T., Samonigg, H., and Moinfar, F. (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449: 24-30
65. Anim, J. T., John, B., Abdulsathar, S. S., Prasad, A., Saji, T., Akhtar, N., Ali, V., and Al-Saleh, M. (2005) Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem. 107, 87-93
66. Sauter, E. R., Lininger, J., Magklara, A., Hewett, J. E., and Diamandis, E. P. (2004) Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer. 108, 588-591
67. Sauter, E. R., Klein, G., Wagner-Mann, C., and Diamandis, E. P. (2004) Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. Cancer Detect. Prev. 28, 27-31
68. Sauter, E. R., Tichansky, D. S., Chervoneva, I., and Diamandis, E. P. (2002) Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. Environ. Health Perspect. 110, 241-246
69. Haiman, C. A., Brown, M., Hankinson, S. E., Spiegelman, D., Colditz, G. A., Willett, W. C., Kantoff, P. W., and Hunter, D. J. (2002) The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 62, 1045-1049
70. Kadouri, L., Easton, D. F., Edwards, S., Hubert, A., Kote-Jarai, Z., Glaser, B., Durocher, F., Abeliovich, D., Peretz, T., and Eeles, R. A. (2001) CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br. J. Cancer. 85, 36-40
71. Menin, C., Banna, G. L., De Salvo, G., Lazzarotto, V., De Nicolo, A., Agata, S., Montagna, M., Sordi, G., Nicoletto, O., Chieco-Bianchi, L., and D'Andrea, E. (2001) Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett. 168, 31-36
72. Spurdle, A. B., Dite, G. S., Chen, X., Mayne, C. J., Southey, M. C., Batten, L. E., Chy, H., Trute, L., McCredie, M. R., Giles, G. G., Armes, J., Venter, D. J., Hopper, J. L., and Chenevix-Trench, G. (1999) Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J. Natl. Cancer. Inst. 91, 961-966
73. Given, H. F., Radbourne, R., Oag, H., Merritt, S., Barcla, E., Hanby, A. M., Lamlum, H., McGrath, J., Curran, C., and Tomlinson, I. P. (2000) The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. Eur. J. Cancer. 36, 533-534
74. Dunning, A. M., McBride, S., Gregory, J., Durocher, F., Foster, N. A., Healey, C. S., Smith, N., Pharoah, P. D., Luben, R. N., Easton, D. F., et al. (1999) No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 20, 2131-2135
75. Spurdle, A. B., Antoniou, A. C., Duffy, D. L., Pandeya, N., Kelemen, L., Chen, X., Peock, S., Cook, M. R., Smith, P. L., Purdie, D. M., et al. (2005) The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 7, R176-R183
76. Wang, W., John, E. M., and Ingles, S. A. (2005) Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol. Biomarkers Prev. 14, 2990-2994
77. Cox, D. G., Blanche, H., Pearce, C. L., Calle, E. E., Colditz, G. A., Pike, M. C., Albanes, D., Allen, N. E., Amiano, P., Berglund, G., et al. (2006) A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) (Online). Breast Cancer Res. 8, R54
78. Giguere, Y., Dewailly, E., Brisson, J., Ayotte, P., Laflamme, N., Demers, A., Forest, V. I., Dodin, S., Robert, J., and Rousseau, F. (2001) Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res. 61, 5869-5874
79. Liede, A., Zhang, W., De Leon Matsuda, M. L., Tan, A., and Narod, S. A. (2003) Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines. Cancer Epidemiol. Biomarkers Prev. 12, 848-852
80. Suter, N. M., Malone, K. E., Daling, J. R., Doody, D. R., and Ostrander, E. A. (2003) Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer. Epidemiol. Biomarkers Prev. 12, 127-135
81. Iobagiu, C., Lambert, C., Normand, M., and Genin, C. (2005) Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res. Treat. 1-7
82. Yu, H., Bharaj, B., Vassilikos, E. J., Giai, M., and Diamandis, E. P. (2000) Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Br. Cancer Res. Treat. 59, 153-161
83. Dagan, E., Friedman, E., Paperna, T., Carmi, N., and Gershoni-Baruch, R. (2002) Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur. J. Hum. Genet. 10, 724-728
84. Kristiansen, M., Langerod, A., Knudsen, G. P., Weber, B. L., Borresen-Dale, A. L., and Orstavik, K. H. (2002) High frequency of skewed X-inactivation in young breast cancer patients. J. Med. Genet. 39, 30-33
85. Rebbeck, T. R., Kantoff, P. W., Krithivas, K., Neuhausen, S., Blackwood, M. A., Godwin, A. K., Daly, M. B., Narod, S. A., Garber, J. E., Lynch, H. T., et al. (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am. J. Hum. Genet. 64, 1371-1377
86. Lillie, E. O., Bernstein, L., Ingles, S. A., Gauderman, W. J., Rivas, G. E., Gagalang, V., Krontiris, T., and Ursin, G. (2004) Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res. 64, 1237-1241
87. Haiman, C. A., Hankinson, S. E., De Vivo, I., Guillemette, C., Ishibe, N., Hunter, D. J., and Byrne, C. (2003) Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res. Treat. 77, 27-36
88. Tran, N., Bharaj, B. S., Diamandis, E. P., Smith, M., Li, B. D., and Yu, H. (2004) Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. Cancer Epidemiol. Biomarkers Prev. 13, 2133-2140
89. Kristiansen, M., Knudsen, G. P., Maguire, P., Margolin, S., Pedersen, J., Lindblom, A., and Orstavik, K. H. (2005) High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet 42, 877-880
90. Poulin, R., Simard, J., Labrie, C., Petitclerc, L., Dumont, M., Lagace, L., and Labrie, F. (1989) Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125, 392-399
91. Panet-Raymond, V., Gottlieb, B., Beitel, L. K., Pinsky, L., and Trifiro, M. A. (2000) Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol. Cell. Endocrinol. 167, 139-150
92. Dimitrakakis, C., Zhou, J., and Bondy, C. A. (2002) Androgens and mammary growth and neoplasia. Fertil. Steril. 77, 26-33
93. Nachtigall, L. E., Raju, U., Banerjee, S., Wan, L., and Levitz, M. (2000) Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 7, 243-250
94. Somboonporn, W., and Davis, S. R. (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr. Rev. 25, 374-388
95. Burger, H. G. (2006) Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause
96. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., et al. (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284, 1354-1356
97. Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., and Boyer, T. G. (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 98, 9587-9592
98. Park, J. J., Irvine, R. A., Buchanan, G., Koh, S. S., Park, J. M., Tilley, W. D., Stallcup, M. R., Press, M. F., and Coetzee, G. A. (2000) Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 60, 5946-5949
99. Yeh, S., Hu, Y. C., Rahman, M., Lin, H. K., Hsu, C. L., Ting, H. J., Kang, H. Y., and Chang, C. (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97, 11256-11261
100. Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., and Tilley, W. D. (1995) Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 13, 1572-1577
101. Teulings, F. A., van Gilse, H. A., Henkelman, M. S., Portengen, H., and Alexieva-Figusch, J. (1980) Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res. 40, 2557-2561
102. Hackenberg, R., Hawighorst, T., Filmer, A., Nia, A. H., and Schulz, K. D. (1993) Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast. Cancer Res. Treat. 25, 217-224
103. Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., Jr., et al. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U. S. A. 98, 4904-4909
104. Ghatge, R. P., Jacobsen, B. M., Schittone, S. A., and Horwitz, K. B. (2005) The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast. Cancer Res. 7, R1036-R1050
105. Kemppainen, J. A., Langley, E., Wong, C. I., Bobseine, K., Kelce, W. R., and Wilson, E. M. (1999) Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 13, 440-454
106. Tyagi, R. K., Lavrovsky, Y., Ahn, S. C., Song, C. S., Chatterjee, B., and Roy, A. K. (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 14, 1162-1174
107. 2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J. Biol. Chem. 276, 42293-42301